CEO Sean Brynjelsen Sells $6.1M in Eton Stock Over Two Days
ETON has more than doubled off its 52-week low of $14.27.
Summary
CEO Sean Brynjelsen sold $6.09 million of Eton Pharmaceuticals stock on August 19-20, adding to a pattern of insider selling despite strong recent earnings.
Key Events · Ownership and Investor Activity · ETON
-
CEO Sells $6.1M in Stock
Sean Brynjelsen sold 100,000 shares for $6,087,773 across four transactions on August 19-20, 2026, at prices ranging from $59.59 to $63.41.
-
Second Major Sale in 90 Days
This follows a $3.8 million sale by Brynjelsen on May 29, 2026, and contributes to a total of $14.5 million in insider selling over the last 90 days.
-
Post-Sale Holdings
After the transactions, Brynjelsen directly owns 1,052,216 shares, down from 1,152,216 shares before the sales.
-
Context: Strong Q2 Results
The sales come one week after Eton reported Q2 revenue of $37.6 million (up 99% YoY) and raised full-year guidance, suggesting the CEO is monetizing gains at elevated prices.
Analysis · ETON · Life Sciences
President and CEO Sean Brynjelsen sold 100,000 shares for $6.09 million on August 19-20, 2026, at prices between $59.59 and $63.41. This is his second major sale in three months, following a $3.8 million sale in May, and comes amid a broader insider distribution pattern totaling over $14.5 million in the last 90 days. The sale represents 0.356% of the company's market cap and reduces his direct holdings to 1,052,216 shares. While the company recently reported strong Q2 results and raised guidance, the CEO's repeated selling at current price levels may temper investor enthusiasm.
At the time of this filing, ETON was trading at $60.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $14.27 to $63.83. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.